Drug Profile
Ciclosporin ophthalmic - AbbVie
Alternative Names: Cyclosporin - AbbVie; Cyclosporin ophthalmic emulsion; Cyclosporine - AbbVie; RESTASIS; Restasis; RESTASIS MULTIDOSE; Restasis X; RestaysisLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer AbbVie; Allergan
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
- Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dry eyes
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 20 Jul 2018 The US Court of Appeals for the Federal Circuit affirms the decision of the US Patent Trial and Appeal Board filed against Allergan by Mylan for patent disputes in USA
- 07 Jun 2018 Launched for Dry eyes in North America (Ophthalmic) prior to June 2018